BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Receives $16.71 Average Target Price from Analysts
Shares of BioXcel Therapeutics, Inc. (NASDAQ:BTAI – Get Free Report) have been given an average recommendation of “Hold” by the seven brokerages that are presently covering the firm, MarketBeat Ratings reports. Four analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 12 month […]
More Stories
Elevance Health, Inc. (NYSE:ELV) Short Interest Update
Elevance Health, Inc. (NYSE:ELV – Get Free Report) saw a large growth in short interest during the month of September....
Arm Holdings plc (NASDAQ:ARM) Given Average Recommendation of “Moderate Buy” by Analysts
Arm Holdings plc (NASDAQ:ARM – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the thirty...
AllianceBernstein Holding L.P. (NYSE:AB) Receives Consensus Rating of “Moderate Buy” from Brokerages
AllianceBernstein Holding L.P. (NYSE:AB – Get Free Report) has been given a consensus rating of “Moderate Buy” by the five...
Aerovate Therapeutics, Inc. (NASDAQ:AVTE) Sees Significant Decrease in Short Interest
Aerovate Therapeutics, Inc. (NASDAQ:AVTE – Get Free Report) was the recipient of a large drop in short interest during the...
180 Life Sciences Corp. (NASDAQ:ATNFW) Short Interest Down 15.9% in September
180 Life Sciences Corp. (NASDAQ:ATNFW – Get Free Report) was the recipient of a large decline in short interest in...
DoubleLine Opportunistic Credit Fund (NYSE:DBL) Short Interest Update
DoubleLine Opportunistic Credit Fund (NYSE:DBL – Get Free Report) was the recipient of a large growth in short interest in...